In the trial, Dupixent ® (dupilumab) ... Regeneron and Sanofi are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes in Phase 3 trials, ...

Dupilumab improved nasal polyp outcomes and asthma symptoms more than omalizumab in patients with CRSwNP and asthma, according to the head-to-head EVEREST phase 4 trial. ... Regeneron, and ...

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 ...

Roche’s IgG2 monoclonal antibody (mAb) astegolimab has yielded mixed results in chronic obstructive pulmonary disease (COPD), ...

"While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for ...

The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly ...

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

SAN FRANCISCO — Among patients with COPD and type 2 inflammation, investigator-reported emphysema did not change benefits seen with dupilumab, according to research presented at the American ...

‍Advancing Medical Innovation Through Regeneron’s Clinical Trials ‍Regeneron is a biotechnology company that has been pushing the boundaries of scientific discovery for nearly four decades.

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed ...